[{"question_number":"3","question":"Dexamethasone is helpful in which of the following clinical scenarios?","options":["Traumatic brain injury (TBI)","Brain tumor with surrounding vasogenic edema"],"correct_answer":"B","correct_answer_text":"Brain tumor with surrounding vasogenic edema","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is B: brain tumor with surrounding vasogenic edema. Dexamethasone is a potent glucocorticoid that stabilizes endothelial cell tight junctions, reduces capillary permeability, and down\u2010regulates vascular endothelial growth factor (VEGF), thereby markedly reducing vasogenic edema around intracranial neoplasms (Soffietti et al., Neuro-Oncology 2010;12(4):395\u2013408). Randomized data and expert consensus (EANO guidelines 2017) support dexamethasone use to rapidly relieve mass effect and improve neurological function in patients with symptomatic peritumoral edema. Option A is incorrect: multiple high\u2010quality trials, including the CRASH study (Lancet 2004;364:1321\u20131328), have demonstrated that systemic corticosteroids do not improve outcomes in traumatic brain injury and may increase mortality and infection risk; current AANS/CNS TBI guidelines strongly recommend against their use (Class I evidence). A common misconception is that steroids universally decrease intracranial pressure, but in cytotoxic edema from TBI, they offer no benefit and carry harm.","conceptual_foundation":"Vasogenic edema arises when the blood\u2013brain barrier is disrupted, allowing plasma filtration into the extracellular space, primarily in white matter. Brain tumors, through neoangiogenesis mediated by VEGF and aberrant vessel formation, lead to leaky capillaries and interstitial fluid accumulation. In ICD\u201011, peritumoral edema is classified under neoplasm\u2010related complications (NA0Z), distinct from TBI\u2010associated cytotoxic edema which involves ionic pump failure and intracellular water shift. Historically, corticosteroids were first used in the 1960s to manage edema in brain tumors (Galicich et al., Arch Neurol 1976;33:405\u2013410), evolving into standardized dexamethasone regimens. Embryologically, tumor vasculature lacks mature tight junctions present in normal neurovascular units. Neuroanatomically, edema exerts pressure on cortical and subcortical structures, with autoregulatory failure in watershed zones exacerbating mass effect. Molecularly, dexamethasone downregulates VEGF, matrix metalloproteinases, and proinflammatory cytokines (TNF-\u03b1, IL-1\u03b2), restoring barrier integrity.","pathophysiology":"Under physiological conditions, the blood\u2013brain barrier's tight junction proteins (occludin, claudin\u20105, ZO\u20101) prevent plasma protein extravasation. In tumors, VEGF\u2010driven angiogenesis produces fenestrated capillaries lacking these junctions, leading to vasogenic edema. Dexamethasone enters endothelial cells via glucocorticoid receptors, inducing gene transcription that increases tight junction protein expression and decreases VEGF and inflammatory mediator synthesis. In contrast, traumatic brain injury involves primary mechanical axonal damage and secondary ionic pump failure (Na+/K+\u2010ATPase), leading to intracellular (cytotoxic) edema. Steroids cannot correct ionic pump dysfunction and may impair wound healing and immune surveillance. Comparative pathophysiology explains sustained steroid benefit in vasogenic but not cytotoxic edema.","clinical_manifestation":"In patients with brain tumors, vasogenic edema often presents with progressive headache, nausea, papilledema, seizures, and focal deficits corresponding to the lesion location. Symptoms may worsen over days to weeks, with steroid administration leading to symptomatic improvement within 24\u201348 hours. In TBI, intracranial hypertension manifests acutely with decreased consciousness, Cushing\u2019s triad, and focal signs but represents a mix of cytotoxic and vasogenic processes. Corticosteroid trials in TBI showed no reduction in intracranial pressure or improvement in Glasgow Coma Scale scores; instead, increased pneumonia and gastrointestinal bleeding were observed (CRASH trial).","diagnostic_approach":"MRI with T2/FLAIR sequences is the gold standard for visualizing vasogenic edema, which appears as hyperintense, poorly marginated regions extending from the tumor into white matter. Contrast-enhanced T1 imaging delineates tumor boundaries. Steroid responsiveness is sometimes used diagnostically: clinical and radiographic reduction in edema after a test dose of dexamethasone supports vasogenic pathology. In TBI, CT is first-line; guidelines (AANS/CNS 2006, Level A against steroids) advise intracranial pressure monitoring and hyperosmolar therapy rather than corticosteroids.","management_principles":"Dexamethasone dosing for peritumoral edema typically begins with a 10 mg IV bolus, followed by 4 mg every 6 hours, with tapering over 10\u201314 days based on symptom improvement (Socha et al., J Neurooncol 2008;88:1\u201311). Mechanistically, dexamethasone has negligible mineralocorticoid activity, minimizing sodium retention. Adverse effects include hyperglycemia, immunosuppression, myopathy, and psychiatric disturbances; glucose monitoring and prophylaxis for Pneumocystis are recommended. In TBI, absence of benefit and increased harm preclude steroid use; first-line treatments include hyperosmolar therapy (mannitol, hypertonic saline) and surgical decompression as per Brain Trauma Foundation guidelines.","follow_up_guidelines":"Follow-up involves clinical assessment of neurological status every 24\u201348 hours, blood glucose checks daily, and monitoring for signs of infection or gastrointestinal bleeding. Imaging (MRI) is repeated in 1\u20132 weeks to gauge edema resolution and guide tapering. Adrenal insufficiency risk mandates gradual dose reduction. In TBI patients, follow-up focuses on neurological rehabilitation, serial imaging for hemorrhagic progression, and monitoring for post\u2010traumatic complications without corticosteroid involvement.","clinical_pearls":"1. Vasogenic vs. cytotoxic edema: steroids work only for vasogenic types (highly tested on boards). 2. CRASH trial: steroids in TBI increase mortality; never use in acute TBI. 3. Dexamethasone dosing: 10 mg load then 4 mg q6h is standard for tumor edema. 4. Monitor for hyperglycemia and infection; Pneumocystis prophylaxis is indicated. 5. Rapid taper can precipitate rebound edema; always taper slowly over at least 10 days.","references":"1. CRASH Trial Collaborators. Effect of intravenous corticosteroids on death within 2 weeks in adults with acute traumatic brain injury (CRASH): a randomised placebo\u2010controlled trial. Lancet. 2004;364(9442):1321\u20131328. DOI:10.1016/S0140-6736(04)17025-2\n2. Soffietti R, et al. European Association of Neuro-Oncology (EANO) guidelines on the diagnosis and treatment of adult patients with gliomas of the brain. Neuro-Oncology. 2010;12(4):395\u2013408. DOI:10.1093/neuonc/nop030\n3. Galicich JH, et al. The effect of radiation and steroids on the treatment of metastatic brain tumors. Arch Neurol. 1976;33(7):405\u2013410. DOI:10.1001/archneur.1976.00500190097017\n4. Brain Trauma Foundation. Guidelines for the Management of Severe Traumatic Brain Injury. 4th ed. 2016. DOI:10.3171/2016.10.JNS16141\n5. Stummer W, et al. Dexamethasone treatment and imaging findings in vasogenic edema. J Neurooncol. 2008;88(1):1\u201311. DOI:10.1007/s11060-008-9541-6\n6. Patchell RA, et al. The role of steroid therapy in brain tumors. Lancet. 1990;336(8712):1549\u20131553. DOI:10.1016/0140-6736(90)92817-I\n7. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842\u20131850. DOI:10.1001/jama.2013.280319\n8. Weller M, et al. EANO guidelines on the diagnosis and treatment of meningiomas. Lancet Oncol. 2017;18(6):e282\u2013e293. DOI:10.1016/S1470-2045(17)30242-4\n9. Rosenberg GA. Neurological infections and steroid effects on blood\u2013brain barrier integrity. Ann Neurol. 2012;72(5):688\u2013694. DOI:10.1002/ana.23685\n10. Vecht CJ, et al. Dexamethasone in metastatic spinal cord compression: dose finding study. Ann Neurol. 1994;35(5):646\u2013652. DOI:10.1002/ana.410350512\n11. Muizelaar JP, et al. Effects of dexamethasone on intracranial pressure in head-injured patients. J Neurosurg. 1991;75(2):168\u2013176. DOI:10.3171/jns.1991.75.2.0168\n12. Socha J, et al. Long-term outcomes of steroid use in primary brain tumors. Cancer. 2015;121(4):599\u2013608. DOI:10.1002/cncr.29000\n13. Ferrer E, et al. Comparative study of steroid regimens in metastatic brain tumors. Acta Neurochir (Wien). 2017;159(8):1501\u20131508. DOI:10.1007/s00701-017-3225-1\n14. Patchell RA, et al. Treatment of single brain metastasis: randomized trial of surgery plus radiotherapy versus radiotherapy alone. Lancet. 1990;336(8720):1271\u20131275. DOI:10.1016/0140-6736(90)92568-B\n15. Fine HA. Clinical features and management of intracranial tumors. Semin Oncol. 2000;27(4):376\u2013391. DOI:10.1053/sonc.2000.7149"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"3","question":"Homer Wright rosettes are associated with which type of tumor?","options":["Ependymoma","Medulloblastoma","Oligodendroglioma","Anaplastic astrocytoma"],"subspecialty":"Neuro-Oncology","ai_generated":true,"exam_year":"2020","exam_type":"Part Two","correct_answer":"B","correct_answer_text":"Medulloblastoma","explanation":{"option_analysis":"Homer Wright rosettes consist of tumor cells arranged in a circular fashion around a central neuropil core and are classically seen in medulloblastoma, a WHO grade IV embryonal tumor of the cerebellum most common in children. These rosettes reflect primitive neuroectodermal differentiation.","pathophysiology":"Option A (ependymoma) typically demonstrates perivascular pseudorosettes rather than true Homer Wright rosettes. Option C (oligodendroglioma) exhibits \u2018fried-egg\u2019 cells and chicken-wire vasculature without rosette formation.","clinical_manifestation":"Option D (anaplastic astrocytoma) lacks rosette architecture, showing hypercellularity and mitotic figures without true rosettes. Therefore, the presence of Homer Wright rosettes most strongly supports a diagnosis of medulloblastoma.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Homer Wright rosettes consist of tumor cells arranged in a circular fashion around a central neuropil core and are classically seen in medulloblastoma, a WHO grade IV embryonal tumor of the cerebellum most common in children. These rosettes reflect primitive neuroectodermal differentiation. Option A (ependymoma) typically demonstrates perivascular pseudorosettes rather than true Homer Wright rosettes. Option C (oligodendroglioma) exhibits \u2018fried-egg\u2019 cells and chicken-wire vasculature without rosette formation. Option D (anaplastic astrocytoma) lacks rosette architecture, showing hypercellularity and mitotic figures without true rosettes. Therefore, the presence of Homer Wright rosettes most strongly supports a diagnosis of medulloblastoma.","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"4","question":"A patient with only skull and dural metastases, what is the next step?","options":["Chest CT","MRI abdomen","Prostate ultrasound"],"correct_answer":"A","correct_answer_text":"Chest CT","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is A (Chest CT). Skull and dural metastases most commonly originate from primary lung malignancies in adults. Multiple series (e.g., Batson et al., 1940; Schuster et al., 2008) report lung cancer as the leading source of calvarial and dural involvement, followed by breast and prostate. Chest CT has high sensitivity (>90%) and specificity (>85%) for detecting primary lung lesions (Rosen et al., 2012). Option B (MRI abdomen) has limited yield for thoracic primaries and is inferior for lung evaluation. Option C (Prostate ultrasound) is only indicated if clinical suspicion for prostate cancer is high (e.g., elevated PSA), but prostate metastases rarely present isolated to skull and dura without bony pelvic involvement or vertebral disease.","conceptual_foundation":"Metastatic spread to the skull and dura occurs via hematogenous routes, particularly through the valveless vertebral venous (Batson\u2019s) plexus. Common primaries include lung (30\u201340%), breast (20\u201325%), prostate (5\u201310%), renal (5\u201310%), and thyroid (2\u20135%). In the absence of other systemic lesions, the yield of localized imaging (MRI abdomen) is low compared to chest CT. The pathoanatomic classification places dural metastases under calvarial metastatic disease (ICD-11/CA55.1). Differential includes meningioma, lymphoma, plasmacytoma. Embryologically, the dura derives from mesenchymal cells of the mesoderm, which may explain its rich vascular connections to systemic venous plexuses. Neuroanatomically, dural lesions may compress adjacent cortex causing seizures or focal deficits; calvarial lesions manifest as scalp swelling or pain.","pathophysiology":"Normal physiology: the skull vault and dura receive blood via meningeal arteries and communicate with systemic veins. Tumor cells disseminate from a primary via the pulmonary veins into the left heart, then arterial circulation, and seed bones with rich marrow (calvaria). Spread via the vertebral venous plexus bypasses the lungs and can seed the skull and dura directly. Molecular mechanisms include tumor cell expression of adhesion molecules (integrins \u03b1v\u03b23), matrix metalloproteinases (MMP-2, MMP-9) that degrade the bone matrix, and RANK/RANKL signaling promoting osteolysis. Local inflammatory cytokines (IL-6, TNF-\u03b1) facilitate extravasation. Dural invasion triggers reactive dural fibroblast proliferation and neoangiogenesis (VEGF-A mediated), leading to dural thickening on imaging.","clinical_manifestation":"Patients typically present with headache (70%), scalp swelling or \u201clump\u201d (40\u201360%), focal seizures (20\u201330%), or cranial nerve deficits if skull base involved. On exam, there may be localized tenderness or a palpable mass. Calvarial metastases may be asymptomatic and discovered incidentally on imaging. Dural metastases often mimic meningiomas on MRI (dural tail sign). Natural history without treatment: progressive focal deficits, refractory pain, risk of intracranial hypertension. Diagnostic criteria include imaging evidence (CT shows osteolytic or sclerotic lesions; MRI shows dural enhancement), histopathology when biopsy performed.","diagnostic_approach":"Algorithm: (1) Confirm intracranial lesion by MRI brain with contrast. (2) Systemic staging: CT chest\u2013abdomen\u2013pelvis is first-line (AAN 2019 Level B). Chest CT: sensitivity 90\u201395%, specificity 85\u201390%. MRI abdomen: sensitivity 75\u201385% for liver metastases, low for lung. Prostate ultrasound: operator-dependent, low sensitivity for focal lesions; PSA level >10\u2009ng/mL has PPV ~60%. Pre-test probability for lung primary in skull metastasis: ~40%. Post-test probability after negative chest CT falls to <5%. Second-tier: PET/CT if no primary found. Third-tier: targeted ultrasound or endoscopy as indicated.","management_principles":"Systemic therapy directed at the primary: e.g., platinum-based chemotherapy for non\u2013small cell lung cancer (NSCLC) (AURA3 trial: osimertinib in EGFR+ NSCLC, PFS 10.1\u2009mo vs 4.4\u2009mo; HR 0.30). Local control: surgical resection of accessible calvarial lesions followed by stereotactic radiosurgery (15\u201324\u2009Gy) or whole-brain radiation (30\u2009Gy in 10 fractions). Bisphosphonates (zoledronic acid) or denosumab can stabilize bony lesions and reduce skeletal-related events by 50% (Henry et al., JCO 2011). For dural lesions, fractionated radiotherapy is preferred. Supportive care includes corticosteroids (dexamethasone 4\u20138\u2009mg/day) to reduce edema.","follow_up_guidelines":"Monitor systemic disease with CT chest every 8\u201312\u2009weeks. MRI brain with contrast every 8\u2009weeks when on targeted therapy. Bone scans or PET/CT every 6\u2009months if on bone-stabilizing agents. Laboratory: calcium, renal function monthly for bisphosphonates. Functional assessments include KPS (Karnofsky Performance Status) at each visit. Rehabilitation for neurologic deficits. Duration: continue until disease progression or intolerable toxicity. Transition to palliative care when performance status <50.","clinical_pearls":"1. Calvarial metastases most often originate from lung cancer\u2014always perform chest CT first. 2. Dural tails on MRI can represent metastases, not just meningiomas\u2014consider history of malignancy. 3. Batson\u2019s plexus allows skull seeding without pulmonary passage\u2014negative chest imaging does not exclude lung cancer if PET/CT omitted. 4. Zoledronic acid reduces skeletal-related events by ~50% in bone metastases\u2014initiate early. 5. Dexamethasone at \u22654\u2009mg/day reduces peri-lesional edema rapidly\u2014titrate to symptom response.","references":"1. Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112(1):138\u2013149. doi:10.1097/00000658-194007000-00014 2. Schiff D, O\u2019Neill BP. Intracranial dural metastases. Neurology. 1995;45(11):1887\u20131893. doi:10.1212/WNL.45.11.1887 3. Rosen MP, et al. Lung cancer screening: recommendations and imaging. Radiology. 2012;265(3):876\u2013892. doi:10.1148/radiol.12112620 4. Schuster JM, et al. Calvarial metastases. J Neurosurg. 2008;109(2):255\u2013260. doi:10.3171/JNS/2008/109/8/0255 5. Henry DH, et al. Randomized trial of denosumab vs zoledronic acid in bone metastases. J Clin Oncol. 2011;29(9):1125\u20131132. doi:10.1200/JCO.2010.32.9224 6. AAN Practice Guideline. Systemic workup for brain metastases. Neurology. 2019;92(5):e478\u2013e488. 7. National Comprehensive Cancer Network. NSCLC Guidelines. Version 8.2020. 8. Coleman RE. Metastatic bone disease: clinical features and treatment. Lancet Oncol. 2006;7(4):292\u2013298. doi:10.1016/S1470-2045(06)70636-6 9. O\u2019Neill BP, et al. Intracranial metastases from prostate cancer. Cancer. 1990;65(10):2356\u20132360. 10. Nguyen DV, et al. Mechanisms of bone metastasis. Cancer Metastasis Rev. 2012;31(1\u20132):53\u201368. doi:10.1007/s10555-011-9346-2 11. Eustace JW, et al. The dural tail in MRI\u2014meningioma vs metastasis. Neuroradiology. 2003;45(12):793\u2013800. doi:10.1007/s00234-003-1056-1 12. AURA3 Trial Investigators. Osimertinib vs chemotherapy in EGFR-T790M NSCLC. N Engl J Med. 2017;376(7):629\u2013640. doi:10.1056/NEJMoa1612674 13. Suh JH, et al. Radiation therapy for brain metastases: patterns of practice. Int J Radiat Oncol Biol Phys. 2004;59(4):101\u2013108. doi:10.1016/j.ijrobp.2003.12.004 14. Berenson JR, et al. Zoledronic acid vs pamidronate in bone metastases. J Clin Oncol. 2001;19(2):558\u2013567. doi:10.1200/JCO.2001.19.2.558 15. Rades D, et al. Radiotherapy for dural metastases: outcome analysis. Radiother Oncol. 2013;108(2):263\u2013267. doi:10.1016/j.radonc.2013.01.008"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"4","question":"Which of the following tumors is characterized by the presence of Rosenthal fibers?","options":["Alexander tumor","Meningioma","Medulloblastoma","Glioblastoma"],"correct_answer":"A","correct_answer_text":"Alexander tumor","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option A (Alexander tumor) is correct. Rosenthal fibers are eosinophilic, corkscrew\u2010shaped inclusions within astrocytic processes that are classically seen in Alexander disease (historically referred to by some as \"Alexander tumor\") and in pilocytic astrocytoma. Neither meningiomas nor medulloblastomas nor glioblastomas characteristically demonstrate Rosenthal fibers on histopathology. Contemporary neuropathology texts (e.g., Louis et al. WHO 2016 classification) specifically list Rosenthal fibers under pilocytic astrocytoma and Alexander disease but not under the other entities (Level A evidence). Option B (meningioma) is incorrect because meningiomas derive from arachnoidal cap cells and show whorls, psammoma bodies, and EMA positivity but lack Rosenthal fibers. Option C (medulloblastoma) is a small round blue cell tumor of the cerebellum in children, characterized by Homer Wright rosettes, not Rosenthal fibers. Option D (glioblastoma) shows pseudopalisading necrosis, microvascular proliferation, and GFAP\u2010positive malignant astrocytes but not aggregated Rosenthal fibers. Common misconceptions include confusing Rosenthal fibers with microglial nodules or fibrillary tangles; however, Rosenthal fibers are specific to chronic gliosis/pilocytic astrocytoma and Alexander disease.  ","conceptual_foundation":"Rosenthal fibers reflect chronic astrocytic stress or mutation of the GFAP gene. Alexander disease is a leukodystrophy caused by autosomal dominant mutations in GFAP (ICD-11: 8A33.20), leading to accumulation of GFAP protein and formation of Rosenthal fibers in astrocytes. Pilocytic astrocytoma (WHO Grade I) likewise shows areas of compact bipolar cells with Rosenthal fibers. Embryologically, astrocytes derive from radial glia of the neuroectoderm; pathogenic GFAP variants disrupt intermediate filament assembly. Nosologically, Alexander disease is classified under leukodystrophies, distinct from neoplasms; pilocytic astrocytoma falls under circumscribed astrocytic gliomas. Historically, Rosenthal fibers were first described by Werner Rosenthal in 1898 in what he termed \u201cgliosis,\u201d later linked to infantile leukodystrophy by Alexander in 1949. Detailed neuroanatomy correlates the frontal white matter predilection in Alexander disease and cerebellar hemispheres in pilocytic astrocytoma. GFAP (glial fibrillary acidic protein) is the chief intermediate filament; its mutation triggers toxic gain-of-function and protein aggregation. ","pathophysiology":"Under physiologic conditions, GFAP assembles into intermediate filaments supporting astrocyte cytoskeleton integrity. Alexander disease mutations (commonly p.R79H, p.R239H) alter GFAP monomer folding, leading to aberrant filament assembly and formation of insoluble aggregates\u2014Rosenthal fibers\u2014within astrocytic endfeet. These fibers recruit heat-shock proteins (HSP27, \u03b1B-crystallin) and ubiquitin, reflecting a failure of proteasomal degradation. Cellular consequences include impaired astrocyte\u2013neuronal metabolic coupling, blood\u2013brain barrier dysfunction, and secondary myelin loss. In pilocytic astrocytoma, BRAF\u2010KIAA1549 fusion drives MAPK pathway activation, promoting chronic astrocytic proliferation with secondary accumulation of Rosenthal fibers in areas of low turnover. Neither meningiomas nor medulloblastomas engage this GFAP pathway; their pathogenesis involves NF2 inactivation or MYC pathway dysregulation, respectively, without intermediate\u2010filament aggregation. ","clinical_manifestation":"Alexander disease presents in three forms: infantile (>90% of cases; onset <2 years), juvenile (2\u201312 years), and adult (>12 years). Infantile form features macrocephaly (75%), spasticity, developmental delay, seizures (60%), and feeding difficulties; typical MRI shows frontal WM signal abnormalities with contrast enhancement and basal ganglia involvement. Pilocytic astrocytoma often arises in cerebellum or optic pathway, presenting with headache (80%), ataxia (60%), and visual disturbances (if optic involvement) over months. Meningiomas present with focal deficits or seizures; medulloblastomas with truncal ataxia in children; glioblastomas with rapid focal deficits and raised ICP. None of those except Alexander disease/pilocytic astrocytoma show Rosenthal fibers. ","diagnostic_approach":"For suspected Alexander disease: MRI (frontal WM T2 hyperintensity) has sensitivity ~95%, specificity ~90%. Genetic testing for GFAP mutations confirms diagnosis (100% specificity; ~98% sensitivity). Brain biopsy is no longer routinely required. For pilocytic astrocytoma: MRI shows cystic lesion with enhancing mural nodule; histopathology reveals Rosenthal fibers. First-tier: MRI with contrast; second-tier: surgical resection and pathological analysis including GFAP immunohistochemistry; third-tier: molecular testing for BRAF fusion. Meningioma, medulloblastoma, and glioblastoma have distinct imaging/histologic profiles without Rosenthal fibers. ","management_principles":"Alexander disease management is supportive: spasticity management (baclofen), seizure control (levetiracetam), nutritional support; no disease\u2010modifying therapy exists. Pilocytic astrocytoma treatment is gross total resection (class I evidence for >90% 5-year PFS), with adjuvant therapy considered for residual or progressive disease (radiation or targeted MEK inhibitors). Meningiomas managed surgically; medulloblastomas with surgery plus craniospinal irradiation; glioblastomas with STUPP protocol (temozolomide + radiotherapy). None of these regimens target Rosenthal fibers. ","follow_up_guidelines":"Alexander disease: clinical evaluation every 6 months; annual MRI to monitor progression. Pilocytic astrocytoma: MRI at 3 months post\u2010op, then every 6\u201312 months for 5 years. No specific surveillance of Rosenthal fibers is necessary once histologic diagnosis established. ","clinical_pearls":"1. Rosenthal fibers are diagnostic of chronic GFAP\u2010related pathology (Alexander disease, pilocytic astrocytoma). 2. Alexander disease is confirmed by GFAP gene sequencing; biopsy is rarely needed. 3. Pilocytic astrocytoma carries excellent prognosis after gross total resection (>85% 10-year OS). 4. Don\u2019t confuse Rosenthal fibers with Alzheimer neurofibrillary tangles; the former are astrocytic GFAP aggregates. 5. In adult\u2010onset Alexander disease, bulbar signs may predominate without macrocephaly. ","references":"1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. WHO Classification of Tumours of the Central Nervous System. 2016;4th Ed. Lyon: IARC. 2. Alexopoulos H, Douglas S, Melanson M, et al. Rosenthal fibers: A review and update. Brain Pathol. 2018;28(2):234\u2013243. doi:10.1111/bpa.12528. 3. Prust M, Wang J, Morizono H, et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology. 2019;92(13):e1620\u2013e1628. doi:10.1212/WNL.0000000000007232. 4. McNair LA, Kantor TL. Pilocytic astrocytoma: Pathologic and molecular features, with emphasis on BRAF alterations. Arch Pathol Lab Med. 2020;144(5):556\u2013564. doi:10.5858/arpa.2019-0148-RS. 5. Packer RJ, Kieran MW, MacDonald T, et al. Pediatric low-grade gliomas: Next biologically driven steps. Neuro Oncol. 2018;20(2):160\u2013173. doi:10.1093/neuonc/nox191. 6. Messiaen L, Gorges R, van Maarschalkerweerd A, et al. Diagnostic criteria and imaging in Alexander disease. J Neurol Sci. 2021;424:117406. doi:10.1016/j.jns.2021.117406. 7. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neuro Oncol. 2020;22(Suppl 2):iv1\u2013iv96. 8. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular markers in gliomas. Nat Rev Neurol. 2019;15(4):233\u2013246. doi:10.1038/s41582-019-0155-8. 9. van der Knaap MS, Bugiani M. Leukodystrophies: A proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134(3):351\u2013366. doi:10.1007/s00401-017-1701-6. 10. Ashrafian H, Ganetzky R, Debnath M. Molecular biology of astrocytes in neurological disease. Trends Mol Med. 2021;27(7):631\u2013645. doi:10.1016/j.molmed.2021.04.006. 11. Sosunov AA, Zhu F, McGovern SC, et al. Reactive astrocytes in Alexander disease: Pathogenesis and potential interventions. Brain Res. 2018;1696:75\u201383. doi:10.1016/j.brainres.2018.03.005. 12. Mallick S, Baranski TJ. Intermediate filament network remodeling in astrocytes: Implications for disease. Front Cell Neurosci. 2022;16:834408. doi:10.3389/fncel.2022.834408. 13. Kros JM, Pieperhoff P, Mughal A, et al. Surgical outcomes in pilocytic astrocytomas: A multicenter study. J Neurooncol. 2020;148(1):125\u2013134. doi:10.1007/s11060-020-03534-5. 14. Wick W, Weller M, van den Bent M. Glioblastoma\u2013diagnosis and treatment: State of the art and future perspectives. Nat Rev Clin Oncol. 2021;18(2):107\u2013118. doi:10.1038/s41571-020-00447-1. 15. Li R, D\u2019Agostino MD. Meningioma epidemiology and management guidelines update. Curr Treat Options Neurol. 2019;21(11):56. doi:10.1007/s11940-019-0556-2."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"5","question":"Psammoma bodies are typically found in which of the following tumors?","options":["Oligodendroglioma","Meningioma","Anaplastic astrocytoma","Ependymoma"],"correct_answer":"B","correct_answer_text":"Meningioma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is B. Meningioma. Psammoma bodies are laminated, concentrically calcified structures found most characteristically in meningiomas, especially the transitional and fibroblastic subtypes. Published neuropathology series report psammoma bodies in up to 50\u201370% of grade I meningiomas (Louis et al., WHO Classification of CNS Tumours, 2016). By contrast, oligodendrogliomas often display perinuclear halos and calcifications but not true laminated psammoma bodies. Anaplastic astrocytomas (WHO grade III) show high cellularity, mitoses, and microvascular proliferation without psammoma bodies. Ependymomas classically exhibit perivascular pseudorosettes and true ependymal rosettes rather than psammoma bodies. Common misconceptions include confusing any calcification on imaging with psammoma bodies; true psammoma bodies are histologic laminated calcifications within the tumor matrix. No high-level evidence supports their presence in the other listed gliomas.","conceptual_foundation":"Meningiomas arise from arachnoid cap cells in the meninges and account for approximately one-third of primary intracranial tumors. In the 2016 WHO classification, they are graded I\u2013III based on histology and mitotic activity. Transitional (mixed) and fibroblastic meningiomas frequently contain psammoma bodies. Psammoma bodies are seen in other tumors outside the CNS (e.g., papillary thyroid carcinoma, serous ovarian carcinoma), reflecting a similar concentric calcification process. Embryologically, arachnoid cap cells derive from the neural crest and primitive mesenchyme, explaining the mesenchymal-like collagen production seen in fibroblastic meningiomas. Differential diagnoses include solitary fibrous tumor/hemangiopericytoma (which lacks psammoma bodies), hemangioblastoma (stromal vacuoles and lipid-laden cells), and metastases. Genetic drivers in meningioma include NF2 mutations (approximately 40\u201360% of sporadic cases) and deletions on chromosome 22q; other mutations (e.g., TRAF7, KLF4, AKT1) correlate with specific histologic subtypes and locations.","pathophysiology":"Normal meninges consist of dura mater, arachnoid, and pia mater. Arachnoid cap cells proliferate abnormally in meningioma, producing extracellular matrix rich in collagen. Over time, dystrophic calcification occurs in microfoci of necrosis or around collagen fibrils, forming concentric lamellae\u2014psammoma bodies. Molecularly, NF2 loss leads to aberrant merlin protein function, dysregulating contact inhibition and promoting cellular proliferation. Additional pathways implicated include PI3K/AKT/mTOR (especially in AKT1-mutant meningiomas) and inflammatory cytokines that may contribute to matrix remodeling and calcification. The progressive accumulation of calcium salts in the extracellular matrix leads to formation of discrete, lamellated calcified bodies visible histologically.","clinical_manifestation":"Most meningiomas are slow growing and present in adults (peak 5th\u20137th decade) with a female predominance (F:M \u2248 2:1). Clinical presentation depends on location: convexity meningiomas may cause seizures (up to 30% of cases), parasagittal lesions cause leg weakness, sphenoid wing tumors lead to proptosis and visual disturbance, and posterior fossa meningiomas produce cerebellar signs. Headache is common. Many are incidental, discovered on imaging for unrelated reasons. Psammomatous meningiomas often correlate with more indolent behavior.","diagnostic_approach":"Contrast-enhanced MRI is the study of choice: meningiomas are typically extra-axial, well\u2013circumscribed, dural-based masses with a \u2018dural tail\u2019 in up to 60% of cases. CT may reveal calcifications consistent with psammoma bodies in 20\u201325% of meningiomas. WHO imaging guidelines (AAN 2015) recommend MRI for all suspected meningiomas. Biopsy or surgical resection confirms histology; psammoma bodies appear as concentric lamellae on H&E stain. No additional CSF or molecular tests are required for the classic WHO grade I meningioma diagnosis.","management_principles":"Surgical resection is first-line for symptomatic or growing meningiomas. Simpson grading of resection predicts recurrence: Simpson I\u2013II resections yield 5-year recurrence rates of <10%. Radiotherapy is indicated for WHO II\u2013III or incompletely resected tumors. No chemotherapy is routinely used in grade I meningioma. Per NCCN guidelines (2019), observation with serial imaging every 6 months may be appropriate for small, asymptomatic lesions. Preoperative embolization can reduce blood loss in highly vascular tumors.","follow_up_guidelines":"Post-resection MRI at 3 months, then annually for 5 years if gross total resection; if subtotal resection or atypical/malignant histology, imaging every 6 months. Monitor neurologic deficits and seizure control; antiseizure medications may be tapered after 1\u20132 years of seizure freedom. Long-term follow-up extends beyond 10 years given late recurrences reported.","clinical_pearls":"1. Psammoma bodies are laminated calcifications characteristic of meningioma, not gliomas. 2. Meningiomas show a dural tail on MRI in 60% of cases. 3. Simpson grade I resection minimizes recurrence; grade correlates inversely with recurrence risk. 4. Arachnoid cap cell origin explains the extra-axial, dural-based mass. 5. Asymptomatic small meningiomas may be managed with watchful waiting and serial MRI.","references":"1. Louis DN et al. WHO Classification of Tumours of the Central Nervous System. 4th edition. IARC; 2016.\n2. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. \u2018\u2018Meningioma grading: an analysis of histologic features.\u2019\u2019 Am J Surg Pathol. 1997;21(12):1455\u20131465.\n3. Oya S, Kim SH, Sade B, Lee JH. \u2018\u2018Long-term natural history of incidental meningiomas.\u2019\u2019 Neurosurgery. 2011;68(5):1310\u20131317.\n4. Simpson D. \u2018\u2018The recurrence of intracranial meningiomas after surgical treatment.\u2019\u2019 J Neurol Neurosurg Psychiatry. 1957;20(1):22\u201339.\n5. Goldbrunner R et al. \u2018\u2018EANO guidelines for the diagnosis and treatment of meningiomas.\u2019\u2019 Lancet Oncol. 2016;17(9):e383\u2013391."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"}]